Z11.52 Insurance Policy Changes

ICD-10 Z11.52 is officially defined as "Encounter for screening for COVID-19." code Z11.52 is referenced in 6 tracked payer policy changes from Aetna, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z11.52 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Nov 2, 2026Medium impact
Exhaled Breath Tests (CPB 0691, reviewed 2026-10-27)
Aetna reviewed its clinical policy on exhaled breath tests (CPB 0691) on 2026-10-27, and the text does not state a new effective date or a specific new requirement. It sets out which breath tests Aetna treats as medically necessary: hydrogen breath testing for lactose intolerance or small intestinal bacterial overgrowth, and exhaled nitric oxide for asthma in members aged 5 and older. Other breath tests, including breath condensate pH, gastric emptying breath tests and exhaled volatile organic compound tests, are listed as not covered or experimental for the indications named.
Aetna · Identified Oct 23, 2026Medium impact
Analysis of Volatile Organic Compounds (CPB 0717, reviewed 2026-10-20)
Aetna considers analysis of volatile organic compounds experimental, investigational or unproven for many indications, including detection of cancer, diagnosis of infection, diagnosis of lung disease such as asthma, diagnosis of tuberculosis and pneumonia, screening for COVID-19, and diagnosis of Parkinson's disease, because the clinical effectiveness of this technique has not been established. The policy states that there is no specific CPT code for analysis of volatile organic compounds. Its ICD-10 table lists diagnosis codes for which the analysis is not covered, and that list is not all-inclusive.
Aetna · Identified Aug 12, 2026Medium impact
Analysis of Volatile Organic Compounds (CPB 0717, reviewed 2025-11-25)
Aetna considers the analysis of volatile organic compounds (VOCs) experimental, investigational or unproven for the listed indications, because the clinical effectiveness of this technique has not been established. The listed indications include detection of bacteriuria, detection of cancer, diagnosis of pneumonia, diagnosis of tuberculosis, diagnosis of lung disease (e.g., asthma), diagnosis of obstructive sleep apnea, and screening for COVID-19. The list is not all-inclusive.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Coronavirus Disease 2019 (COVID-19) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Testing
Blue Cross & Blue Shield of Mississippi covers FDA-approved COVID-19 RT-PCR testing using an upper respiratory specimen when it is medically appropriate for individuals with signs and symptoms compatible with COVID-19 without an alternative explanatory diagnosis. The same testing is medically appropriate for asymptomatic individuals with known or suspected recent exposure when their provider determines it is appropriate, and before elective surgeries and procedures involving the mouth, nose, oropharynx, nasopharynx, respiratory tract, gastrointestinal tract, or requiring general anesthesia or monitored anesthesia care (MAC). COVID-19 RT-PCR testing not approved by the FDA, including any test authorized under an EUA, is considered investigational, and FDA-approved testing performed for screening of asymptomatic individuals is considered not medically necessary. The policy was reviewed on 07/01/2026 with statements unchanged, and the code reference was updated to remove CPT codes 0240U and 0241U.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)
The February 2022 Health First Colorado provider bulletin (B2200475) covers several changes. Effective February 1, 2022, claims requiring electronic visit verification (EVV) go through pre-payment review, and claims without the needed EVV records may deny with EOB 3054. The bulletin also describes at-home OTC COVID-19 test billing under HCPCS E1399 with modifier U1 from January 15, 2022, requires the ordering provider's NPI on DMEPOS claims effective July 1, 2022, and notes that 24 physician-administered drug codes became subject to prior authorization effective January 18, 2022.
Blue Cross Blue Shield of Wyoming · Identified Jun 19, 2026Medium impact
NEW! Screening for COVID-19 Diagnosis Guidance
BCBS Wyoming has updated COVID-19 diagnostic testing coding guidance with new ICD-10 codes and clarified coverage rules. The policy specifies that asymptomatic and pre-surgical COVID-19 testing is covered when medically appropriate, but not for return-to-work or surveillance purposes.

Watch Z11.52

Get one email when a payer policy names Z11.52, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z11.52?

There are 6 tracked policy changes affecting code Z11.52, including updates from Aetna, Blue Cross & Blue Shield of Mississippi, Colorado Medicaid. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z11.52?

Payers that have issued tracked updates for code Z11.52 include: Aetna, Blue Cross & Blue Shield of Mississippi, Colorado Medicaid, Blue Cross Blue Shield of Wyoming.

How do I get notified when code Z11.52 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z11.52. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z11.52?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Exhaled Breath Tests (CPB 0691, reviewed 2026-10-27)

Analysis of Volatile Organic Compounds (CPB 0717, reviewed 2026-10-20)

Analysis of Volatile Organic Compounds (CPB 0717, reviewed 2025-11-25)

Coronavirus Disease 2019 (COVID-19) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Testing

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)

NEW! Screening for COVID-19 Diagnosis Guidance

What insurance policy changes affect code Z11.52?

Which payers have updated policy for code Z11.52?

How do I get notified when code Z11.52 policy changes?

Why do payers change policies for code Z11.52?